Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: marcher who wrote (160452)	7/22/2020 11:51:48 AM
From: TobagoJack	Read Replies (1) \| Respond to of 217852

That << looks more like 2700 than 1000, at this point >> is a wide range within which to make mistakes. Speaking of wide range and mistakes, this day I ordered two sets of several of re-strike (original die / punch) Qing (circa last emperor) Dynasty and early Republic (1911-) silver coins but all re-struck in gold. China, the dynasty and the Republic (as opposed to the People’s Republic) did use silver as monetary ‘thing’ but both considered going on gold standard. Only 100 coins of each die produced. The coin designs are well known in China, but the re-strike coins are not available as the dies were produced in Japan, and somehow ended up in Perth Mint. There is an arbitrage opportunity I am fairly sure. Also ordered the last two HK-domiciled Homer Simpson coins 2020 “DOH” w/ the ‘O’ done in donut, which I thought important for the kids to remember. I so like the idea of Krugerrands that I ordered more. However, I did not feel like paying for any of it, and so arranged w/ counter-party who might be one of those RobinHooders, or some nefarious sort trying to goose TSLA shares, and shorted TSLA calls and puts in some proportion as I determined by putting back of left hand to forehead whilst the right hand’s fingers were tapping away on Cloud-ATM machine. About half of the wager should blow up on the counter-party by Friday 10:00pm Cape Town time. I hope Elon’s company can get to 2700, but after end-July, and gold corrects to 1000. Call me an agnostic optimist. I do need more coins, but shall do something after TSLA Q2 result announcement this night. The lemon remains good unless anything happens to key-man Elon. finance.yahoo.com

To: marcher who wrote (160452)	7/29/2020 4:48:50 PM
From: TobagoJack	Read Replies (1) \| Respond to of 217852

Re <<more like 2700 than 1000>> Almost for sure you are right, except for the suppression possibility If we are to once and for all prove no-suppression, this is the time for the market to do so. In the meantime, Kodak is not as sexy as Tesla, but same idea ... bloomberg.com Kodak Craziness Is Captured in One Word: Really?Day traders seem to love the company’s switch to pharmaceuticals. Good luck with that. Max NisenJuly 29, 2020, 10:59 AM PDT Kodak’s stock surge on a risky pivot to pharmaceuticals is the perfect picture of Robinhood gone wild. Photographer: Daniel Acker/Bloomberg LISTEN TO ARTICLE Kodak, the once-iconic photo company that’s been languishing for years, surprised the world this week by announcing a pivot into the pharmaceuticals business with a $765 million head start from the U.S. government. Somehow, that was enough to send the stock soaring more than 1,000% and add more than $1 billion to the company’s market value. Really? Let’s discuss. The Defense Production Act loan, announced Tuesday, is part of a Trump administration effort to bring the manufacture of drug ingredients back to U.S. shores to reduce dependence on other countries and ensure consistent supply. It's a reasonable if challenging policy goal. The loan and new business line for Eastman Kodak Co. isn't, however, anything close to a justification for its massive share-price gains — whatever day traders and Robinhood investors may say. Kodak is attempting to enter a low-margin commodity market with no particular advantage outside of the current administration's industrial policy. Unless the government money spigot keeps flowing, it's hard to imagine the company ever living up to its lofty valuation. Worth a SnapshotKodak shares soared Wednesday after receiving a loan to make drug ingredients Source: Bloomberg Many of the world's pharmaceutical ingredients come from China or India. This has become a concern in recent years because of quality-control issues and the recent specter of pandemic-related shortages. However, shifting the supply chain back to the U.S. isn't the work of a few loans or a few years. Re-shoring sounds appealing, but it's challenging to successfully break into a commodity business from a standing start even with a boost from the government. And drug ingredients made in America by an inexperienced new entrant are likely to be more expensive than those available abroad in the absence of extreme and rare supply shocks. Many large generic drugmakers that also make and use drug ingredients have been facing significant pricing pressure and slashing costs for years; few are likely to consistently buy American from a new source unless the government forces them. What’s more, higher ingredient costs would potentially filter through to higher drug prices, which is not exactly a popular idea. Part of the enthusiasm may stem from the fact that Kodak reportedly aims to make drug ingredients used in the fight against Covid-19, including hydroxychloroquine, a medicine that President Donald Trump continues to tout as a possible treatment even though it has repeatedly failed to show a benefit in clinical trials. To turn that into an investment thesis for Kodak, you have to believe that the medicine will finally succeed in a well-controlled trial, or that off-label prescriptions will be common. You have to think that the company, which has been out of the drug business for decades, will be able to retrofit factories and significantly ramp up production before vaccines or more effective treatments emerge. You have to believe that the company can compete on cost giants that have been in this business for decades or that Congress will pass a mandate handing it a market. It's unclear if anyone's buying Kodak because they truly believe in the long-term potential of this project, as opposed to just day trading. Either way, good luck. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. To contact the author of this story: Max Nisen at mnisen@bloomberg.net To contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.net Before it's here, it's on the Bloomberg Terminal. LEARN MORE Sent from my iPad